ABSI: Bull Flag detected on 9 Jul 2026

ABSI is forming a bull flag pattern with strong structural integrity (15.0/15 structure score). Trading at $11.10 with key support at $10.41 and resistance at $12.06, the pattern sits near the upper end of its recent range. Breakout score of 10.7/13 and volume score of 11.5/12 indicate a tight, well-defined flag on reduced volume (81% of 20-day average), consistent with consolidation dynamics. The 74.49% win probability suggests this setup has favorable historical precedent. RSI at 68.41 shows strength without overbought extremes.

On June 24, 2026, Absci announced a $100 million underwritten offering priced at $7.41 per share, with proceeds supporting advancement of ABS-201 across androgenetic alopecia and endometriosis. The company successfully dosed all four planned healthy volunteer single ascending dose cohorts of its HEADLINE Phase 1/2a trial with favorable safety data, with preliminary pharmacokinetic modeling supporting ABS-201's targeted dosing interval of two to three injections over six months. Absci anticipates reporting preliminary safety, tolerability, and PK data in Q2 2026. As of March 31, 2026, cash and equivalents totaled $125.7 million, sufficient to fund operations into the first half of 2028. Stock traded up significantly post-offering, suggesting positive institutional reception and confidence in clinical pipeline.

A successful bull flag breakout would see ABSI close above the $12.06 resistance level on volume expansion. The measured move target (conservative) of $11.47 implies initial upside to the top of the flag range; sustained breakout momentum could drive further extension toward prior resistance. The setup fails on a close below $10.41 support, which would negate the bullish structure. With 74.49% historical win probability, this pattern type has demonstrated edge, though recent 1-week decline of -4.23% shows short-term weakness requiring confirmation of reversal momentum.

The $100 million secondary offering closed around June 25, 2026, creating near-term dilution at $7.41 per share. Current price of $11.10 sits 50% above the offering price, raising questions about sustained valuation and potential profit-taking by new institutional investors. Beta of 1.69 indicates above-market volatility—any sector or biotech rotation could amplify downside. Biotech-stage companies face binary execution risk on clinical trials; failure of ABS-201 trials in H2 2026 would devastate the setup. High ATR of 1.17 (10.54% of price) suggests wide swings. Market regime remains bearish (-0.27) despite bullish healthcare sector backdrop, creating macro headwind. High relative volume (only 81% of average) could suggest weak conviction into the flag.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.